Loading
A phase 1/2 trial of PRJ1-3024 in melanoma, run by Zhuhai Yufan Biotechnologies Co., Ltd, now recruiting.
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma is a phase 1/2 interventional study registered as NCT06727630 by Zhuhai Yufan Biotechnologies Co., Ltd, with 40 participants planned, started 2024-03-14 and due to reach its primary completion in 2025-04-30. Interventions recorded: PRJ1-3024.
Shares Zhuhai Yufan Biotechnologies and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.